Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer

References

• MathasSMisteliTThe dangers of transcriptionCell200913961047104920005797
   PubMed Web of Science ®Google Scholar
• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• PetrylakDPPractical guide to the use of chemotherapy in castration resistant prostate cancerCan J Urol2014212 Supp 1778324775728
   PubMed Web of Science ®Google Scholar
• MontgomeryRBMostaghelEAVessellaRMaintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growthCancer Res200868114447445418519708
   PubMed Web of Science ®Google Scholar
• FizaziKScherHIMolinaACOU-AA-301 InvestigatorsAbiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyLancet Oncol2012131098399222995653
   PubMed Web of Science ®Google Scholar
• LabrieFLuu-TheVBelangerAIs dehydroepiandrosterone a hormone?J Endocrinol2005187216919616293766
   PubMed Web of Science ®Google Scholar
• LubikAAGunterJHHollierBGIGF2 increases de novo steroidogenesis in prostate cancer cellsEndocr Relat Cancer201320217318623319492
   PubMed Web of Science ®Google Scholar
• HoflandJvan WeerdenWMSteenbergenJDitsNFJensterGde JongFHActivin A stimulates AKR1C3 expression and growth in human prostate cancerEndocrinology2012153125726573423024260
   PubMed Web of Science ®Google Scholar
• ChunJYNadimintyNDuttSInterleukin-6 regulates androgen synthesis in prostate cancer cellsClin Cancer Res200915154815482219638459
   PubMed Web of Science ®Google Scholar
• LubikAAGunterJHHollierBGIGF2 increases de novo steroidogenesis in prostate cancer cellsEndocr Relat Cancer201320217318623319492
   PubMed Web of Science ®Google Scholar
• LockeJAGunsESLehmanMLArachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistanceProstate201070323925119790237
   PubMed Web of Science ®Google Scholar
• StanbroughMBubleyGJRossKIncreased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancerCancer Res20066652815282516510604
   PubMed Web of Science ®Google Scholar
• MizokamiAKohEIzumiKProstate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosteroneEndocr Relat Cancer20091641139115519608712
   PubMed Web of Science ®Google Scholar
• KellyWKHalabiSCarducciMRandomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401J Clin Oncol201230131534154022454414
   PubMed Web of Science ®Google Scholar
• MathasSMisteliTThe dangers of transcriptionCell200913961047104920005797
   PubMed Web of Science ®Google Scholar
• LinjaMJSavinainenKJSaramakiORTammelaTLVessellaRLVisakorpiTAmplification and overexpression of androgen receptor gene in hormone-refractory prostate cancerCancer Res20016193550355511325816
   PubMed Web of Science ®Google Scholar
• HaapalaKKuukasjarviTHyytinenERantalaIHelinHJKoivistoPAAndrogen receptor amplification is associated with increased cell proliferation in prostate cancerHum Pathol200738347447817217995
   PubMed Web of Science ®Google Scholar
• LeeJHKangMWangHEndostatin inhibits androgen- independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stressFASEB J20173141608161928069826
   PubMed Web of Science ®Google Scholar
• AroraVKSchenkeinEMuraliRGlucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockadeCell201315561309132224315100
   PubMed Web of Science ®Google Scholar
• ShiotaMTakeuchiASongYY-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expressionEndocr Relat Cancer201118450551721652770
   PubMed Web of Science ®Google Scholar
• YangMWangJWangLEstrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cellsProstate201575131363137526015225
   PubMed Web of Science ®Google Scholar
• De MiguelFLeeSOOnateSAGaoACStat3 enhances transactivation of steroid hormone receptorsNucl Recept200311312904256
   PubMedGoogle Scholar
• JinRJLhoYConnellyLThe nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growthCancer Res200868166762676918701501
   PubMed Web of Science ®Google Scholar
• NadimintyNLouWSunMAberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cellsCancer Res20107083309331920388792
   PubMed Web of Science ®Google Scholar
• BalbasMDEvansMJHosfieldDJOvercoming mutation-based resistance to antiandrogens with rational drug designElife20132e0049923580326
   PubMed Web of Science ®Google Scholar
• DehmSMTindallDJAlternatively spliced androgen receptor variantsEndocr Relat Cancer2011185R183R19621778211
   PubMed Web of Science ®Google Scholar
• JoshiJBPatelDMortonDJInactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52Mol Oncol201711433735728252832
   PubMed Web of Science ®Google Scholar
• KaracostaLGKuroskiLAHofmannWANucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cellsProstate201676329430626552607
   PubMed Web of Science ®Google Scholar
• AzadAAEiglBJMurrayRNKollmannsbergerCChiKNEfficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patientsEur Urol2015671232925018038
   PubMed Web of Science ®Google Scholar
• ZhouHJYanJLuoWSRC-3 is required for prostate cancer cell proliferation and survivalCancer Res200565177976798316140970
   PubMed Web of Science ®Google Scholar
• JozwikKMCarrollJSPioneer factors in hormone-dependent cancersNat Rev Cancer201212638138522555282
   PubMed Web of Science ®Google Scholar
• WangTSongWChenYFlightless I homolog represses prostate cancer progression through targeting androgen receptor signalingClin Cancer Res20162261531154426527749
   PubMed Web of Science ®Google Scholar
• WangSGaoJLeiQProstate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancerCancer Cell20034320922114522255
   PubMed Web of Science ®Google Scholar
• GelmanIHAndrogen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinasesInt J Biol Sci201410662062624948875
   PubMed Web of Science ®Google Scholar
• MateoJBoysenGBarbieriCEDNA repair in prostate cancer: biology and clinical implicationsEur Urol201771341742527590317
   PubMed Web of Science ®Google Scholar
• SchiewerMJGoodwinJFHanSDual roles of PARP-1 promote cancer growth and progressionCancer Discov20122121134114922993403
   PubMed Web of Science ®Google Scholar
• Kote-JaraiZLeongamornlertDSaundersEBRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patientsBr J Cancer201110581230123421952622
   PubMed Web of Science ®Google Scholar
• KokontisJMLinHPJiangSSAndrogen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2PLoS One2014910e10917025271736
   PubMed Web of Science ®Google Scholar
• LevesqueEHuangSPAudet-WalshEMolecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progressionClin Cancer Res201319369970923186779
   PubMed Web of Science ®Google Scholar
• MitsiadesNSungCCSchultzNDistinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumorsCancer Res201272236142615222971343
   PubMed Web of Science ®Google Scholar
• ShiotaMBishopJLNipKMHsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancerCancer Res201373103109311923492367
   PubMed Web of Science ®Google Scholar
• IzumiKFangLYMizokamiATargeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activationEmbo Mol Med2013591383140123982944
   PubMed Web of Science ®Google Scholar
• KarkeraJSteinerHLiWThe anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I studyProstate201171131455146521321981
   PubMed Web of Science ®Google Scholar
• LeeSOLouWNadimintyNLinXGaoACRequirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cellsProstate200564216016715678501
   PubMed Web of Science ®Google Scholar
• WaughDJWilsonCThe interleukin-8 pathway in cancerClin Cancer Res200814216735674118980965
   PubMed Web of Science ®Google Scholar
• TaichmanRSCooperCKellerETPientaKJTaichmanNSMcCauleyLKUse of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to boneCancer Res20026261832183711912162
   PubMed Web of Science ®Google Scholar
• ShenHSchusterRLuBWaltzSELentschABCritical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growthProstate200666161721172816941672
   PubMed Web of Science ®Google Scholar
• WangJLuYWangJKochAEZhangJTaichmanRSCXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathwayCancer Res20086824103671037619074906
   PubMed Web of Science ®Google Scholar
• SinghRKLokeshwarBLThe IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growthCancer Res20117193268327721398406
   PubMed Web of Science ®Google Scholar
• WangJShiozawaYWangJThe role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancerJ Biol Chem200828374283429418057003
   PubMed Web of Science ®Google Scholar
• PasquinelliAEMicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationshipNat Rev Genet201213427128222411466
   PubMed Web of Science ®Google Scholar
• SinghAHappelCMannaSKTranscription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesisJ Clin Invest201312372921293423921124
   PubMed Web of Science ®Google Scholar
• HirokiEAkahiraJSuzukiFChanges in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomasCancer Sci2010101124124919891660
   PubMed Web of Science ®Google Scholar
• JalavaSEUrbanucciALatonenLAndrogen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancerOncogene201231414460447122266859
   PubMed Web of Science ®Google Scholar
• YangLLinCJinClncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programsNature2013500746459860223945587
   PubMed Web of Science ®Google Scholar
• YangFZhangHMeiYWuMReciprocal regulation of HIF-1alpha and lincRNA-p21 modulates the Warburg effectMol Cell20145318810024316222
   PubMed Web of Science ®Google Scholar
• ScaravilliMPorkkaKPBrofeldtAMiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2Prostate201575879880525731699
   PubMed Web of Science ®Google Scholar
• PrensnerJRIyerMKBalbinOATranscriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progressionNat Biotechnol201129874274921804560
   PubMed Web of Science ®Google Scholar
• YapKLLiSMunoz-CabelloAMMolecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4aMol Cell201038566267420541999
   PubMed Web of Science ®Google Scholar
• BeltranHRickmanDSParkKMolecular characterization of neuroendocrine prostate cancer and identification of new drug targetsCancer Discov20111648749522389870
   PubMed Web of Science ®Google Scholar
• ArsovCWinterCRabenaltRAlbersPCurrent second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxelUrol Oncol201230676277120884252
   PubMed Web of Science ®Google Scholar
• RyanCJSaylorPJEverlyJJSartorOBone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new dataOncologist201419101012101825232039
   PubMed Web of Science ®Google Scholar
• MassariFMainesFModenaACastration resistant prostate cancer (CRPC): state of the art, perspectives and new challengesAnticancer Agents Med Chem201313687288623272970
   PubMed Web of Science ®Google Scholar
• SuarezCMorales-BarreraRRamosVRole of immunotherapy in castration-resistant prostate cancer (CRPC)BJU Int2014113336737523650874
   PubMed Web of Science ®Google Scholar
• DarJAEisermannKMasoodiKZN-terminal domain of the androgen receptor contains a region that can promote cytoplasmic localizationJ Steroid Biochem Mol Biol2014139162424099702
   PubMed Web of Science ®Google Scholar
• NarayananSSrinivasSFeldmanDAndrogen-glucocorticoid interactions in the era of novel prostate cancer therapyNat Rev Urol2016131476026643568
   PubMed Web of Science ®Google Scholar
• YeDHuangYZhouFA phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and RussiaAsian J Urol201742758529264210
   PubMed Web of Science ®Google Scholar
• TorenPJKimSPhamSAnticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancerMol Cancer Ther2015141596925351916
   PubMed Web of Science ®Google Scholar
• FizaziKJonesROudardSPhase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5J Clin Oncol201533772373125624429
   PubMed Web of Science ®Google Scholar
• SolitDBScherHIRosenNHsp90 as a therapeutic target in prostate cancerSemin Oncol200330570971614571418
   PubMed Web of Science ®Google Scholar
• BaylotVKatsogiannouMAndrieuCTargeting TCTP as a new therapeutic strategy in castration-resistant prostate cancerMol Ther201220122244225622893039
   PubMed Web of Science ®Google Scholar
• O’MalleyKJLangmannGAiJRamos-GarciaRVessellaRLWangZHsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistanceProstate201272101117112322161776
   PubMed Web of Science ®Google Scholar
• HeSZhangCShafiAAPotent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expressionInt J Oncol2013421354323152004
   PubMed Web of Science ®Google Scholar
• ZoubeidiAZardanABeraldiECooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activityCancer Res20076721104551046517974989
   PubMed Web of Science ®Google Scholar
• IschiaJSaadFGleaveMThe promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancerCurr Opin Urol201323319420023385973
   PubMed Web of Science ®Google Scholar
• TranCOukSCleggNJDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancerScience2009324592878779019359544
   PubMed Web of Science ®Google Scholar
• LiuCLouWZhuYNiclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancerClin Cancer Res201420123198321024740322
   PubMed Web of Science ®Google Scholar
• YamashitaSLaiKPChuangKLASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptorsNeoplasia2012141748322355276
   PubMed Web of Science ®Google Scholar
• LibertiniSJTepperCGRodriguezVAsmuthDMKungHJMudryjMEvidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independenceCancer Res200767199001900517909000
   PubMed Web of Science ®Google Scholar
• SunHMediwalaSNSzafranATManciniMAMarcelliMCUDC-101, a novel inhibitor of full-length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: mechanism of action and in vivo efficacyHorm Cancer20167319621026957440
   PubMed Web of Science ®Google Scholar
• TeplyBAAntonarakisESNovel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancerCurr Opin Endocrinol Diabetes Obes201623327929026978733
   PubMed Web of Science ®Google Scholar
• AndersenRJMawjiNRWangJRegression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptorCancer Cell201017653554620541699
   PubMed Web of Science ®Google Scholar
• BanuelosCALalATienAHCharacterization of niphatenones that inhibit androgen receptor N-terminal domainPLoS One201499e10799125268119
   PubMed Web of Science ®Google Scholar
• SadarMDWilliamsDEMawjiNRSintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cellsOrg Lett200810214947495018834139
   PubMed Web of Science ®Google Scholar
• MichelsJEnzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial-there is no significant reduction in death (Yet)J Clin Oncol2017351123
   Web of Science ®Google Scholar
• PollockJAWardellSEParentAAInhibiting androgen receptor nuclear entry in castration-resistant prostate cancerNat Chem Biol2016121079580127501397
   PubMed Web of Science ®Google Scholar
• YuEYWildingGPosadasEPhase II study of dasatinib in patients with metastatic castration-resistant prostate cancerClin Cancer Res200915237421742819920114
   PubMed Web of Science ®Google Scholar
• BianchiniDOmlinAPezaroCFirst-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancerBr J Cancer2013109102579258624169353
   PubMed Web of Science ®Google Scholar
• CarverBSChapinskiCWongvipatJReciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancerCancer Cell201119557558621575859
   PubMed Web of Science ®Google Scholar
• LiJKarkiAHodgesKBCotargeting polo-like kinase 1 and the Wnt/beta-catenin signaling pathway in castration-resistant prostate cancerMol Cell Biol201535244185419826438599
   PubMed Web of Science ®Google Scholar
• ZhangLSLumLDelivery of the porcupine inhibitor WNT974 in miceMethods Mol Biol2016148111111727590157
   PubMedGoogle Scholar
• HollenhorstPCMcIntoshLPGravesBJGenomic and biochemical insights into the specificity of ETS transcription factorsAnnu Rev Biochem20118043747121548782
   PubMed Web of Science ®Google Scholar
• NhiliRPeixotoPDepauwSTargeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidinesNucleic Acids Res201341112513823093599
   PubMed Web of Science ®Google Scholar
• VainioPGuptaSKetolaKArachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancerAm J Pathol2011178252553621281786
   PubMed Web of Science ®Google Scholar
• RahimSBeauchampEMKongYBrownMLToretskyJAUrenAYK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasionPLos One201164e1934321559405
   PubMed Web of Science ®Google Scholar
• KimSJKimSICurrent treatment strategies for castration-resistant prostate cancerKorean J Urol201152315716521461278
   PubMedGoogle Scholar
• CaffoOFratinoLBarbieriRPemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II studyUrol Oncol201331218018621803618
   PubMed Web of Science ®Google Scholar
• ShiotaMYokomizoAEtoMTaxane chemotherapy for hormone-naive prostate cancer with its expanding role as breakthrough strategyFront Oncol2015530426793621
   PubMed Web of Science ®Google Scholar
• BotrelTEClarkOLima PompeoACEfficacy and safety of combined Androgen Deprivation Therapy (ADT) and docetaxel compared with ADT alone for metastatic hormone-naive prostate cancer: a systematic review and meta-analysisPLoS One2016116e015766027308831
   PubMed Web of Science ®Google Scholar
• MitaACDenisLJRowinskyEKPhase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumorsClin Cancer Res200915272373019147780
   PubMed Web of Science ®Google Scholar
• YapTAPezaroCJde BonoJSCabazitaxel in metastatic castration-resistant prostate cancerExpert Rev Anticancer Ther20121291129113623098113
   PubMed Web of Science ®Google Scholar
• DarshanMSLoftusMSThadani-MuleroMTaxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancerCancer Res201171186019602921799031
   PubMed Web of Science ®Google Scholar
• BadrisingSvan der NoortVvan OortIMClinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatmentCancer2014120796897524382803
   PubMed Web of Science ®Google Scholar
• BianchiniDLorenteDRodriguez-VidaAAntitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abirateroneEur J Cancer2014501788424074764
   PubMed Web of Science ®Google Scholar
• ZhongDZhangHJJiangYDSaikosaponin-d: a potential chemotherapeutics in castration resistant prostate cancer by suppressing cancer metastases and cancer stem cell phenotypesBiochem Biophys Res Commun2016474472272927155154
   PubMed Web of Science ®Google Scholar
• NeliusTMartinez-MarinDHirschJPigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancerCell Death Dis20145e121024810046
   PubMed Web of Science ®Google Scholar
• GulleyJLMadanRADeveloping immunotherapy strategies in the treatment of prostate cancerAsian J Urol20163427828529264196
   PubMedGoogle Scholar
• KantoffPWSchuetzTJBlumensteinBAOverall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancerJ Clin Oncol20102871099110520100959
   PubMed Web of Science ®Google Scholar
• BeckerJTOlsonBMJohnsonLEDaviesJGDunphyEJMcNeelDGDNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancerJ Immunother201033663964720551832
   PubMed Web of Science ®Google Scholar
• KaranDVan VeldhuizenPCombination immunotherapy with prostate GVAX and ipilimumab: safety and toxicityImmunotherapy20124657758022788125
   PubMed Web of Science ®Google Scholar
• ShoreNDMantzCADosoretzDEBuilding on sipuleucel-T for immunologic treatment of castration-resistant prostate cancerCancer Control201320171623302902
   PubMed Web of Science ®Google Scholar
• AntonarakisESCombining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancerAsian J Androl201214452052122580638
   PubMed Web of Science ®Google Scholar
• KwonEDDrakeCGScherHICA184-043 InvestigatorsIpilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialLancet Oncol201415770071224831977
   PubMed Web of Science ®Google Scholar
• SanlorenzoMVujicIDaudAPembrolizumab cutaneous adverse events and their association with disease progressionJAMA Dermatol2015151111206121226222619
   PubMed Web of Science ®Google Scholar
• MadanRAKarzaiFHNingYMPhase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerBJU Int2016118459059726780387
   PubMed Web of Science ®Google Scholar
• MadanRAKarzaiFHNingYMPhase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerBJU Int2016118459059726780387
   PubMed Web of Science ®Google Scholar
• ChuGCZhauHEWangRRANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonizationEndocr Relat Cancer201421231132624478054
   PubMed Web of Science ®Google Scholar
• RyanCJSaylorPJEverlyJJSartorOBone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new dataOncologist201419101012101825232039
   PubMed Web of Science ®Google Scholar
• MahajanKCoppolaDRawalBAck1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancerJ Biol Chem201228726221122212222566699
   PubMed Web of Science ®Google Scholar
• ChiKNGleaveMEFazliLA phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancerClin Cancer Res201218123407341322553344
   PubMed Web of Science ®Google Scholar
• SmithDCSmithMRSweeneyCCabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialJ Clin Oncol201331441241923169517
   PubMed Web of Science ®Google Scholar
• WyceADegenhardtYBaiYInhibition of BET bromodomain proteins as a therapeutic approach in prostate cancerOncotarget20134122419242924293458
   PubMed Web of Science ®Google Scholar
• CoudeMMBraunTBerrouJBET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cellsOncotarget2015619176981771225989842
   PubMedGoogle Scholar
• WyceADegenhardtYBaiYInhibition of BET bromodomain proteins as a therapeutic approach in prostate cancerOncotarget20134122419242924293458
   PubMed Web of Science ®Google Scholar
• SirtoriCRAescin: pharmacology, pharmacokinetics and therapeutic profilePharmacol Res200144318319311529685
   PubMed Web of Science ®Google Scholar
• PiaoSKangMLeeYJCytotoxic effects of escin on human castration-resistant prostate cancer cells through the induction of apoptosis and G2/M cell cycle arrestUrology2014844982.e1982.e7
   PubMed Web of Science ®Google Scholar